Akathisia

Akathisia
Other namesAcathisia
Common sign of akathisia
Medical specialtyNeurology, psychiatry
SymptomsFeelings of restlessness, inability to stay still, uneasy
ComplicationsViolence or suicidal thoughts
DurationShort- or long-term
CausesAntipsychotics, selective serotonin reuptake inhibitors, metoclopramide, reserpine
Diagnostic methodBased on symptoms
Differential diagnosisAnxiety, tic disorders, tardive dyskinesia, dystonia, medication-induced parkinsonism, restless leg syndrome
TreatmentReduce or switch antipsychotics, correct iron deficiency, exercise
MedicationDiphenhydramine, gabapentin, trazodone, benzodiazepines, benztropine, mirtazapine, beta blockers
FrequencyRelatively common

Akathisia (/æ.kə.ˈθɪ.si.ə/ a-kə-THI-see-ə) is a movement disorder. It makes a person feel inner restlessness, usually along with mental distress and/or being unable to sit still.

Symptoms

Usually, the legs are most prominently affected. People with akathisia may fidget, rock back and forth, or pace, while some may just have an uneasy feeling in their bodies.

In the most severe cases, people may refuse to take akathisia-causing medications; they might also have worsening psychiatric symptoms, and, because of this, aggression, violence, and/or suicidal thoughts.

Studies suggest that akathisia is also associated with threatening behaviour and physical aggression in mentally disordered patients. However, scientists have not found any systemic link between akathisia and suicidal or homicidal behavior.

Apart from these few low-quality studies, there is another more recent and better quality study (a systematic review from 2021). It concludes akathisia cannot be reliably linked to the presence of suicidal behavior in patients treated with antipsychotic medication.

Causes

Antipsychotic medications, particularly the first generation antipsychotics, are a leading cause. Selective serotonin reuptake inhibitors, metoclopramide, and reserpine, may cause akathisia - though any medication that lists agitation as a side effect may trigger it. It may also occur upon stopping antipsychotics.

Effects

According to the Cleveland Clinic:

Akathisia is the most common movement disorder associated with [psychiatric] medication, particularly antipsychotic (neuroleptic) medications. Approximately 24% of people who have schizophrenia and are taking medication for it have chronic akathisia. In one study, akathisia rates were 39% in people taking clozapine and 45% among people taking first-generation antipsychotics (FGA).

References

  1. ↑ Salem H, Nagpal C, Pigott T, Teixeira AL (2017). "Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges". Curr Neuropharmacol (Review). 15 (5): 789–798. doi:10.2174/1570159X14666161208153644. PMC 5771055. PMID 27928948.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 Lohr, JB; Eidt, CA; Abdulrazzaq Alfaraj, A; Soliman, MA (December 2015). "The clinical challenges of akathisia". CNS Spectrums (Review). 20 (Suppl 1): 1–14, quiz 15–6. doi:10.1017/S1092852915000838. PMID 26683525. S2CID 4253429.
  3. ↑ Kaufman, David Myland; Milstein, Mark J. (2012). Kaufman's Clinical Neurology for Psychiatrists E-Book. Elsevier Health Sciences. p. 429. ISBN 978-1-4557-4004-8.
  4. 1 2 3 4 Laoutidis, ZG; Luckhaus, C (May 2014). "5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis". The International Journal of Neuropsychopharmacology (Review). 17 (5): 823–32. doi:10.1017/S1461145713001417. PMID 24286228.
  5. ↑ Poyurovsky M, Weizman A (June 2020). "Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists". Drugs (Review). 80 (9): 871–882. doi:10.1007/s40265-020-01312-0. PMID 32385739. S2CID 218541032.
  6. ↑ Forcen, FE; Matsoukas, K; Alici, Y (February 2016). "Antipsychotic-induced akathisia in delirium: A systematic review". Palliative & Supportive Care (Review). 14 (1): 77–84. doi:10.1017/S1478951515000784. PMC 5516628. PMID 26087817.
  7. 1 2 Thomas, JE; Caballero, J; Harrington, CA (2015). "The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis". Current Neuropharmacology (Review). 13 (5): 681–91. doi:10.2174/1570159x13666150115220221. PMC 4761637. PMID 26467415.
  8. ↑ Stubbs, J. H.; Hutchins, D. A.; Mountjoy, C. Q. (2000). "Relationship of akathisia to aggressive and self-injurious behaviour: A prevalence study in a UK tertiary referral centre". International Journal of Psychiatry in Clinical Practice. 4 (4): 319–325. doi:10.1080/13651500050517894. ISSN 1365-1501. PMID 24926584. S2CID 26486432.
  9. 1 2 3 Kalniunas, Arturas; Chakrabarti, Ipsita; Mandalia, Rakhee; Munjiza, Jasna; Pappa, Sofia (3 December 2021). "The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review". Neuropsychiatric Disease and Treatment. 17: 3489–3497. doi:10.2147/NDT.S337785. ISSN 1176-6328. PMC 8651045. PMID 34887662.
  10. ↑ "MISSD - The Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin - Akathisia Support". missd.co. Retrieved 26 August 2022.
  11. ↑ "Akathisia: What It Is, Symptoms, Causes & Treatment". Cleveland Clinic. Retrieved 2 October 2025.